Phosphagenics Sp ADR (PPGNY) 0.5640 $PPGNY Acne Vulgaris

New Post Public Reply Private Reply Replies (0) Message Board

Oct 10, 2015 at 12:55 PM

Phosphagenics Sp ADR (PPGNY) 0.5640 $PPGNY

Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 3.02 (-0.04), FOMX: 6.84 (+0.17), GSK: 40.22 (+0.06), PRTK: 21.00 (+0.25), AGN: 274.84 (-1.32), PVCT: 0.56 (unch), DERM: 26.14 (+0.81), NBRV: 9.86 (+0.09)

Osteoarthritis Pain Pipeline Report 2015 - 26 Companies & 46 Drug Profiles
M2 - Fri Jul 10, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8bmth/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - Astellas Pharma Inc. - Boehringer Ingelheim GmbH - Bone Medical Limited - Eli Lilly and Company - Flexion Therapeutics, Inc. - Grunenthal GmbH - iCeutica, Inc. - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (lidocaine tetracaine) - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - cebranopadol - celecoxib - CGS-125 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - ibuprofen - LY-2951742 - meloxicam - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A - oxycodone ER For more information visit http://www.researchandmarkets.com/research/w8...oarthritis
FLXN: 15.19 (+0.27), PFE: 33.24 (+0.15), AMGN: 149.59 (-0.31), AMPE: 3.04 (+0.05), LLY: 86.14 (+2.37), NKTR: 11.34 (+0.56), TEVA: 58.96 (-0.28), ABBV: 55.64 (-0.40), POZN: 6.29 (+0.10), REGN: 503.92 (+12.71)

Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vw27k3/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline plc - Melinta Therapeutics, Inc - Phosphagenics Limited Drug Profiles - CG-400549 - Debio-1450 - Debio-1452 - delafloxacin - fusidic acid - GSK-2140944 - iclaprim mesylate - lanopepden - Small Molecule for Skin Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - tedizolid phosphate For more information visit http://www.researchandmarkets.com/research/vw...cated_skin
GSK: 40.22 (+0.06), CEMP: 29.31 (+0.29)

Peripheral Neuropathic Pain - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9893bq/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AnaBios Corporation - Astellas Pharma Inc. - Eli Lilly and Company - GW Pharmaceuticals plc - Nektar Therapeutics - Pfizer Inc. - Phosphagenics Limited - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/9893bq/peripheral
PFE: 33.24 (+0.15), LLY: 86.14 (+2.37), NKTR: 11.34 (+0.56)

Seborrhea Pipeline Review, H1 2015 - 4 Companies & 6 Drug Profiles
M2 - Fri Jun 12, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pvb5km/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biomar Microbial Technologies - EpiPharm AG - Maruho Co., Ltd. - Phosphagenics Limited Drug Profiles - A-101 - EPI-SK14 - IB-07A081 - IB-07A085 - ketoconazole - lanoconazole For more information visit http://www.researchandmarkets.com/research/pvb5km/seborrhea

Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 13.00 (+0.10), FOMX: 6.84 (+0.17), PVCT: 0.56 (unch), JNJ: 95.37 (+0.29), DERM: 26.14 (+0.81), ANAC: 115.06 (+2.13), XNCR: 12.28 (-0.13), REGN: 503.92 (+12.71), AQXP: 12.90 (+0.11), BMY: 61.44 (+0.93), GSK: 40.22 (+0.06), VRX.TO: 227.56 (+4.67), CBPO: 97.22 (+2.50), MRK: 50.95 (-0.07), CCXI: 6.45 (+0.02), CLTX: 36.01 (+16.34), CELGZ: 1.74 (+0.04), NVS: 91.90 (-0.71)

Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 227.56 (+4.67)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lawyers Juggle AI's Promise and Perils in 2026

AI's Growing Pains in the Legal Arena Looks like the legal eagles are getting a run for their money with AI entering the courtroom. Bloomberg Law's 2026 AI in Practice report dives deep into this legal labyrinth. You got attorneys leaning on AI to keep the gears turning, but they're also clutching their pearls over potential pitfalls. Trust Issues: Humans vs. Machines The...

Siemens Set to Acquire Lauterbach in Strategic Move

Siemens Seizing New Opportunities with Lauterbach Acquisition Bam! Siemens is on the move, folks, snapping up Lauterbach to bolster its semiconductor design arsenal. Now, if you’ve got your eyes glued to innovation in chip design, like yours truly, then strap in because this merger is more than just a footnote on some dusty tech page. It's a game-changer when it comes...

Jinko Solar Joins B20 Summit: Energy Forefront Focus

Jinko Solar's Invitation to the B20 Summit Never a dull moment in the solar space, especially when Jinko Solar, a big shot in clean energy, jumps into the spotlight at the B20 Summit in the U.S. Awash with high-profile discussions, Jinko's not just chatting—it's the only photovoltaic firm strutting its stuff in D.C. with gutsy calls for energy reform. Key Takeaways from...

Paulex Bio's Grant Fuels Bold Diabetes Research Push

Cracking the Diabetes Code: A New Hope Emerging It ain't every day you hear about a biotech outfit snagging an NIH Fast-Track grant with the potential to upend diabetes treatment, but Paulex Bio's recent score turns heads. Their brainchild, PAL-119, promises to tackle diabetes not by slapping a band-aid on symptoms, but by getting to the rotten core of the disease: the...

Shukla MD's New Concierge Program Boosts Patient Care

Shifting the Healthcare Paradigm Imagine a healthcare world where doctors actually have the time to listen and engage with you beyond just scribbling notes in haste. That's what's brewing over in Westchester, where Dr. Rachana and Dr. Vaishalee Shukla are putting the old-school patient-doctor relationship front and center with their Hybrid Choice concierge program. Run...

NHTSA, Ad Council Unveil New Anti-Buzzed Driving PSAs

Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...

Cognizant Boosts Claude AI with 25,000 Pro Workforce

Moving AI from Theory to Practice You know, AI isn't about just keeping up with the hype; it's about shoving those algorithms right where they can do the most good—right at the core of business operations. And that’s precisely what Cognizant's cooking up with their fresh-off-the-press Claude Frontier Capability Group. They’ve thrown more than 25,000 pros into the...

Bandwidth's SI Innovations: A New Dawn or Just Hype?

Bandwidth Unleashes Super Intelligence at Reverb Right off the bat, Bandwidth's Reverb showcase was enough to stir up some excitement in the air. The company laid out a feast of technological advancements with their Super Intelligence (SI) innovations that claim to redefine how enterprises communicate. But here's the rub—while these developments sound thrilling, the...

Parachute Health Urges HME Transformation Through Collaboration

The Road to Digital Unity in HME Cranking through the gears of the healthcare industry is no mean feat, but Parachute Health seems ready to throw some fresh oil on the machine. In a landscape riddled with complexities, they're sounding the call for a more unified digital infrastructure in the Home Medical Equipment (HME) sector through their latest white paper. We're...

What's at Stake: Pearl Diver's Q3 2026 Earnings Call

Upcoming Unveiling: Pearl Diver's Latest Financials Heads up, folks. November 16 can't come soon enough for those keeping tabs on Pearl Diver Credit Company Inc. (NYSE: PDCC, PDPA). The bigwigs over there are planning to spill the beans on their third quarter 2026 financial results. They'll kick things off before the market even has its first cup of java on Monday morning...